Data Anticipated For Bugula Neritina-Based Bryostatin-1 Drug for Alzheimer’s Disease

Data Anticipated For Bugula Neritina-Based Bryostatin-1 Drug for Alzheimer’s Disease
shutterstock_145005193Another investigational drug trial for the treatment of Alzheimer's is set to release key findings within the next few months. Neurotrope, Inc. recently announced the closure of their Phase 2a clinical trial of Bryostatin-1, as the last patient enrolled in the study was administered the drug. The trial was conducted under an Investigational New
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *